NCT03151603

Brief Summary

It is well known that "over-treatment" of straightforward infections should be avoided as far as possible. Evidence-based data on non antibiotic treatment options for common conditions are therefore needed urgently. This randomised-controlled double blind trial examines whether initial herbal treatment with Uva Ursi, and antibiotic treatment only if symptoms persist, reduces antibiotic consumption in uncomplicated urinary tract infections (UTI) without a negative effect on symptom course and rate of recurrent UTIs. In total, 430 patients presenting with typical UTI symptoms will be included by their GPs and receive randomised either herbal treatment with uva ursi (antibiotics only if symptoms persist), or initial antibiotic treatment. Patients record symptom severity and drug intake in a diary and complete a final questionnaire after 28 days.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
398

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started May 2017

Typical duration for phase_4

Geographic Reach
1 country

47 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 3, 2017

Completed
7 days until next milestone

First Submitted

Initial submission to the registry

May 10, 2017

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 12, 2017

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 19, 2019

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

June 20, 2019

Completed
Last Updated

November 27, 2019

Status Verified

November 1, 2019

Enrollment Period

2 years

First QC Date

May 10, 2017

Last Update Submit

November 26, 2019

Conditions

Keywords

Uva Ursifosfomycinuncomplicated urinary tract infection of women

Outcome Measures

Primary Outcomes (2)

  • antibiotic courses

    number of antibiotic courses from day 0 to day 28

    day 0-28

  • symptom burden

    symptom burden (AUC) from day 0 to day 7

    day 0-7

Secondary Outcomes (22)

  • early relapses

    day 0-14

  • recurrent UTI

    day 15-28

  • symptom resolution

    day 4 and 7

  • symptom sum score by patients' questionnaire

    day 0-7

  • symptom burden for dysuria

    day 0-7

  • +17 more secondary outcomes

Study Arms (2)

Uva Ursi

EXPERIMENTAL

placebo to fosfomycin: 3 g granules orally 1x1 (day 0) and Uva Ursi: 105 mg (Arctuvan®) 3x2 tablets orally from day 0 for 5 days

Drug: ArctuvanDrug: Placebo to Fosfomycin

fosfomycin

ACTIVE COMPARATOR

fosfomycin (Monuril®): 3 g granules orally 1x1 (day 0), and placebo to Uva Ursi: 3x2 tablets orally from day 0 for 5 days If the patient returns with persistent/recurrent symptoms, antibiotic therapy according to the sensitivity test.

Drug: FosfomycinDrug: Placebo to Arctuvan

Interventions

application of a herbal drug

Uva Ursi

application of an antibiotic drug

fosfomycin

application of Placebo to Arctuvan

fosfomycin

application of Placebo to Fosfomycin

Uva Ursi

Eligibility Criteria

Age18 Years - 75 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Women (18-75 years) with suspected UTI
  • at least two symptoms of UTI (dysuria, urgency of micturition, frequency, lower abdominal pain)
  • Written informed consent

You may not qualify if:

  • signs of complicated UTI (e. g. temperature \> 38°C, loin tenderness)
  • conditions that may lead to complicated infections (i.e. renal diseases, patients with urinary catheter)
  • pregnancy/ breastfeeding
  • current self-medication with UU preparations e.g. z.B. Cystinol®, Uvalysat®, Arctuvan®
  • antibiotic use in the last 7 days
  • previous UTI in the past 2 weeks
  • history of pyelonephritis
  • contraindications for trial drugs
  • serious diseases
  • inability to understand trial Information
  • current participation in another clinical trial or participation in another clinical trial within the last 4 weeks

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (47)

Hausarztpraxis Dr. Raby

Achim, 28832, Germany

Location

General Practice Aden

Braunschweig, Germany

Location

General Practice Scheffer

Braunschweig, Germany

Location

General Practice Coutelle

Bremen, Germany

Location

General Practice Schelp

Bremen, Germany

Location

General Practice Dickow

Burgwedel, Germany

Location

General Practice Kiwit-Putzer

Burgwedel, Germany

Location

Praxis Zietz

Celle, 29221, Germany

Location

General Practice Kutzsche

Emmerthal, Germany

Location

Praxis Dr. Bahr

Gieboldehausen, 37434, Germany

Location

General Practice Müller

Gillersheim, Germany

Location

Institute of General Medicine, University Medical Center Goettingen

Göttingen, 37073, Germany

Location

Praxisgemeinschaft Jacob / Kling

Göttingen, 37083, Germany

Location

General Practice Keske

Göttingen, Germany

Location

General Practice Koch

Göttingen, Germany

Location

General Practice Kolb

Göttingen, Germany

Location

General Practice Lang

Göttingen, Germany

Location

General Practice Lückerath

Göttingen, Germany

Location

Praxis Dr. Egner

Hanover, 30161, Germany

Location

Institute of General Medicine, MHH Hannover

Hanover, 30625, Germany

Location

General Practice Barth

Hanover, Germany

Location

General Practice Löber

Hardegsen, Germany

Location

Gemeinschaftspraxis Dres Schlesier / Eckhardt

Heilbad Heiligenstadt, 37308, Germany

Location

Gemeinschaftspraxis Hartleb / Stöcking

Heilbad Heiligenstadt, 37308, Germany

Location

Praxis Dr. Koch

Heilbad Heiligenstadt, 37308, Germany

Location

Praxisgemeinschaft Seitz / Eckert

Herzberg, 37412, Germany

Location

General Practice Wilde

Hildesheim, Germany

Location

Praxisgemeinschaft Stoltz / Raddatz

Höxter, 37671, Germany

Location

General Practice Beverungen

Höxter, Germany

Location

Gemeinschaftspraxis Kasperczyk / Schindewolf-Lensch

Isernhagen-Süd, 30916, Germany

Location

General Practice Franz

Katlenburg-Lindau, Germany

Location

Praxis Dr. Ohlendorf

Langenhagen, 30851, Germany

Location

General Practice Ertel

Langwedel, Germany

Location

General Practice Wehrbein

Lemförde, Germany

Location

General Practice Lindenblatt

Neustadt, Germany

Location

Hausarztzentrum Nörten

Nörten-Hardenberg, 37176, Germany

Location

General Practice Preiskorn

Rehburg-Loccum, Germany

Location

General Practice Meier-Ahrens

Rosdorf, Germany

Location

General Practice Woitschek

Salzgitter, Germany

Location

General Practice Beulshausen

Sattenhausen, Germany

Location

General Practice Schulte

Scheeßel, Germany

Location

General Practice Böttcher

Schwanewede, Germany

Location

General Practice Albrecht

Springe, Germany

Location

General Practice Wolf

Uslar, 37170, Germany

Location

General Practice Schmiemann

Verden an der Aller, Germany

Location

General Practice Annweiler

Waake, Germany

Location

General Practice Stegemann

Wunstorf, Germany

Location

Related Publications (2)

  • Gagyor I, Hummers E, Schmiemann G, Friede T, Pfeiffer S, Afshar K, Bleidorn J. Herbal treatment with uva ursi extract versus fosfomycin in women with uncomplicated urinary tract infection in primary care: a randomized controlled trial. Clin Microbiol Infect. 2021 Oct;27(10):1441-1447. doi: 10.1016/j.cmi.2021.05.032. Epub 2021 Jun 7.

  • Afshar K, Fleischmann N, Schmiemann G, Bleidorn J, Hummers-Pradier E, Friede T, Wegscheider K, Moore M, Gagyor I. Reducing antibiotic use for uncomplicated urinary tract infection in general practice by treatment with uva-ursi (REGATTA) - a double-blind, randomized, controlled comparative effectiveness trial. BMC Complement Altern Med. 2018 Jul 3;18(1):203. doi: 10.1186/s12906-018-2266-x.

MeSH Terms

Conditions

Urinary Tract Infections

Interventions

Fosfomycin

Condition Hierarchy (Ancestors)

InfectionsUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital Diseases

Intervention Hierarchy (Ancestors)

OrganophosphonatesOrganophosphorus CompoundsOrganic Chemicals

Study Officials

  • Eva Hummers-Pradier, Prof. Dr.

    University Medical Center Göttingen

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Quality Assurance Staff Unit Clinical Trials

Study Record Dates

First Submitted

May 10, 2017

First Posted

May 12, 2017

Study Start

May 3, 2017

Primary Completion

May 19, 2019

Study Completion

June 20, 2019

Last Updated

November 27, 2019

Record last verified: 2019-11

Locations